CRISPR/Cas9 Gene Therapy Innovation: Targeting HPV16 Oncogene Gene for Cervical Cancer Prevention

Muhammad Rafi Pratama Shidiq; Aghniya Nur Rizka Fadila; Alifah Mustari

doi:10.63142/ijeti.v1i1.239

Authors

Muhammad Rafi Pratama Shidiq Universitas Muhammadiyah Bandung Author
Aghniya Nur Rizka Fadila Universitas Muhammadiyah Bandung Author
Alifah Mustari Universitas Muhammadiyah Bandung Author

DOI:

https://doi.org/10.63142/ijeti.v1i1.239

Keywords:

CRISPR-Cas9, Human Papillomavirus (HPV), Kanker Serviks, Protein onkogen E6 & E7

Abstract

Human Papillomavirus (HPV) is a causative agent of cervical cancer. Approximately 60% of cervical cancers are caused by the infection of HPV-16. Cervical cancer is the second most common cancer affecting women. Various treatments and therapies are being explored to treat cervical cancer, but there is still a need for safer, more effective, and affordable technologies. CRISPR-Cas9 is a modern biotechnology technology derived from bacterial immune mechanisms to combat viruses and phages. This mechanism can be applied as a therapeutic medium, as it allows for specific and precise genome editing. The aim of this literature review is to determine the potential and effectiveness of CRISPR-Cas9 as a therapeutic agent for cervical cancer. The method used involves a literature study, based on searches on official websites such as Pubmed, Google Scholar, and other official journals with the keywords “CRISPR-Cas9” and “Cervical Cancer.” The results indicate that CRISPR can target the Cas9 protein to deactivate the oncogenes E6 and E7 in HPV-16, thereby promoting cell cycle arrest and apoptosis. Various studies have been developed to improve the side effects associated with CRISPR-Cas9. However, research on CRISPR-Cas9 has shown a reduction in cancer tissue and increased apoptosis. This method is effective for cancer treatment and needs further investigation to reduce the incidence of cervical cancer.

Author Biographies

Muhammad Rafi Pratama Shidiq, Universitas Muhammadiyah Bandung

Universitas Muhammadiyah Bandung
Aghniya Nur Rizka Fadila, Universitas Muhammadiyah Bandung

Universitas Muhammadiyah Bandung
Alifah Mustari, Universitas Muhammadiyah Bandung

Universitas Muhammadiyah Bandung

References

Angenline, W. K. (2020). CRISPR – Inovasi Biologi Molekuler dan Medis yang Kontroversia. CDK-248, 47(3), 218–221.

Boshart, M., Gissmann, L., Ikenberg, H., Kleinheinz, A., Scheurlen, W., & zur Hausen, H. (1984). A new type of papillomavirus DNA, its presence in genital cancer biopsies and in cell lines derived from cervical cancer. EMBO Journal, 3, 1151–1157.

Broutian, T. R., Jiang, B., Li, J., Akagi, K., Gui, S., Zhou, Z., et al. (2020). Human papillomavirus insertions identify the PIM family of serine/threonine kinases as targetable driver genes in head and neck squamous cell carcinoma. Cancer Letters, 476, 23–33.

Conway, M. J., Alam, S., Ryndock, E. J., Cruz, L., Christensen, N. D., Roden, R. B. S., & Meyers, C. (2009). Perakitan yang bergantung pada gradien redoks yang membentang di jaringan dari asli virion virus papiloma manusia tipe 16. Journal of Virology, 83, 10515–10526.

Da Silva, D. M., Eiben, G. L., Fausch, S. C., Wakabayashi, M. T., Rudolf, M. P., Velders, M. P., & Kast, W. M. (2001). Cervical cancer vaccines: Emerging concepts and developments. Journal of Cellular Physiology, 186, 169–182.

Durst, M., Gissmann, L., Ikenberg, H., & zur Hausen, H. (1983). A papillomavirus DNA from a cervical carcinoma and its prevalence in cancer biopsy samples from different geographic regions. Proceedings of the National Academy of Sciences USA, 80, 3812–3815.

Dunne, E. F., & Park, I. U. (2013). HPV and HPV-associated diseases. Infectious Disease Clinics of North America, 27(4), 765–778.

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2015). Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. International Journal of Cancer, 136, E359–E386.

Hu, Z., Yu, L., Zhu, D., Ding, W., Wang, X., Zhang, C., et al. (2014). Gangguan HPV16-E7 oleh sistem CRISPR/Cas menginduksi apoptosis dan penghambatan pertumbuhan pada sel kanker serviks manusia positif HPV16. BioMed Research International, 2014, 612823. https://doi.org/10.1155/2014/612823

Hsu, P. D., Lander, E. S., & Zhang, F. (2014). Development and applications of CRISPR–Cas9 for genome engineering. Cell, 157(6), 1262–1278.

Jiang, F., & Doudna, J. A. (2017). CRISPR–Cas9 structures and mechanisms. Annual Review of Biophysics, 46, 505–529.

Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science, 337, 816–821.

Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A., & Liu, D. R. (2016). Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature, 533(7603), 420–424.

Ling, K., Yang, L., Yang, N., Chen, M., Wang, Y., Liang, S., Li, Y., Jiang, L., Yan, P., & Liang, Z. (2020). Gene targeting of HPV18 E6 and E7 synchronously by nonviral transfection of CRISPR/Cas9 system in cervical cancer. Human Gene Therapy Methods, 31(5–6), 297–308.

Makarova, K. S., Wolf, Y. I., Alkhnbashi, O. S., Costa, F., Shah, S. A., & Saunders, S. J. (2015). An updated evolutionary classification of CRISPR–Cas systems. Nature Reviews Microbiology, 13(11), 722–736. https://doi.org/10.1038/nrmicro3569

Moody, C. A., & Laimins, L. A. (2010). Human papillomavirus oncoproteins: Pathways to transformation. Nature Reviews Cancer, 10, 550–560.

Mueller, C., & Flotte, T. R. (2008). Clinical gene therapy using recombinant adeno-associated virus vectors. Gene Therapy, 15, 858–863.

Narisawa-Saito, M., & Kiyono, T. (2007). Basic mechanisms of high-risk human papillomavirus-induced carcinogenesis: Roles of E6 and E7 proteins. Cancer Science, 98, 1505–1511.

Pulecio, J., Verma, N., Mejía-Ramírez, E., Huangfu, D., & Raya, A. (2017). CRISPR/Cas9-based engineering of the epigenome. Cell Stem Cell, 21(4), 431–447.

Redman, M., King, A., Watson, C., & King, D. (2016). What is CRISPR/Cas9? Archives of Disease in Childhood – Education and Practice, 101(4), 213–215.

Rodríguez-Rodríguez, D. R., Ramírez-Solís, R., Garza-Elizondo, M. A., Garza-Rodríguez, M. L., & Barrera-Saldaña, H. A. (2019). Genome editing: A perspective on the application of CRISPR/Cas9 to study human diseases. International Journal of Molecular Medicine, 3(4), 1559–1574. https://doi.org/10.3892/ijmm.2019.4112

Stanley, M. A. (2012). Genital human papillomavirus infections: Current and prospective therapies. Journal of General Virology, 93(4), 681–691.

Wei, Y., Zhao, Z., & Ma, X. (2022). Description of CRISPR-Cas9 development and its prospects in human papillomavirus-driven cancer treatment. Frontiers in Immunology, 13, 1037124.

Zhan, T., Rindtorff, N., Betge, J., Ebert, M. P., & Boutros, M. (2019). CRISPR/Cas9 for cancer research and therapy. Seminars in Cancer Biology, 55, 106–119. https://doi.org/10.1016/j.semcancer.2018.04.001

Zhang, F., Wen, Y., & Guo, X. (2014). CRISPR/Cas9 for genome editing: Progress, implications and challenges. Human Molecular Genetics, 23(R1), R40–R46. https://doi.org/10.1093/hmg/ddu125

Zhen, S., Lu, J. J., Wang, L. J., Sun, X. M., Zhang, J. Q., Li, X., et al. (2016). In vitro and in vivo synergistic therapeutic effect of cisplatin with human papillomavirus16 E6/E7 CRISPR/Cas9 on cervical cancer cell line. Translational Oncology, 9(6), 498–504.

Zhong, S., Zhang, Y., Yin, X., & Di, W. (2019). CDK7 inhibitor suppresses tumor progression through blocking the cell cycle at the G2/M phase and inhibiting transcriptional activity in cervical cancer. OncoTargets and Therapy, 12, 2137–2147.